Overview
With $400 million in assets under management, H.I.G. BioHealth Partners invests in a broad range of healthcare companies across multiple sectors and stages of development. Our seasoned investment team has extensive and diverse experience in big pharma, small biotech, medical devices, diagnostics, basic science, clinical research, and technology transfer. We invest in companies developing novel products for significant unmet medical needs more >
Portfolio
Recent News
- Tue, Jan 12th, 2021 — CardioFocus Invited to Participate in 23rd Annual ICR Conference and Needham Virtual…
- Mon, Jan 11th, 2021 — CardioFocus® Annouces Expanded Distribution Partnership with Microport™ CRM to Include…
- Mon, Jan 4th, 2021 — Angelini Pharma Acquires Arvelle Therapeutics to Create a Leading European Innovator in Central…
- Mon, Dec 21st, 2020 — Neurana Pharmaceuticals Announces First Patient Enrolled in Phase 3, RESUME-1 Study
- Tue, Dec 8th, 2020 — Neurana Pharmaceuticals Announces Top-Line Results from Tolperisone Phase 1 CNS Effects Study
- Tue, Nov 24th, 2020 — Neurana Pharmaceuticals Announces Publication in the Journal of Pain Research
- Thu, Oct 22nd, 2020 — Nevakar Announces FDA Approval for Ephedrine Sulfate Injection as Ready-to-Use Vials
- Wed, Jul 8th, 2020 — H.I.G. Capital Acquires Project Informatica
- Thu, May 21st, 2020 — Results of a Randomised Study Showing that Adjunctive Cenobamate Significantly Improved Seizure…
- Wed, May 13th, 2020 — Leiters Awarded a Group Purchasing Agreement by Comprehensive Pharmacy Services